Therapeutic modality refers to defining medicine by its molecular feature.
Before biotechnology, most medicines were derived from chemical compounds called “small molecules”. Druggable targets and diseases requiring classical small molecule drugs were limited then.
Now, biotechnology has ushered in a new era of drug discovery by enabling its industries to use recombinant human proteins for various treatments. For example, “monoclonal antibodies” are proteins that bind to specific target molecules, with more than 70 monoclonal antibodies currently approved to treat diseases. Chugai has pioneered this field of engineered monoclonal antibodies to realize the next generation of antibody therapeutics.
Meanwhile, as small molecule drugs are taken orally and can penetrate cell membranes, it cannot target intracellular protein-protein interactions. On the other hand, monoclonal antibody drugs can target these interactions but require inoculation via injection and cannot penetrate cells. In response, Chugai also established a new domain of therapeutics through engineered cyclic peptides with “Mid-size molecules” that can achieve all three. These molecules can target druggable diseases previously eluded by small molecules and monoclonal antibodies.
At CPR, we strive to engineer innovative and groundbreaking therapeutic modalities for patients facing critical illnesses around the world.
Drugging the Undruggable By Technology
Novel technology enables us to expand from current drug targets and engineer unique modes of action to address unmet medical needs.
Chugai’s Proprietary Drug Discovery Technology
Details of Chugai’s proprietary antibody engineering and cyclic peptide technology to discover novel monoclonal antibody and Mid-size molecule drugs.
T-Cell Redirecting Antibody
Our Strategy for Drug Discovery Research
A presentation on our mid-term business plan and strategy for Drug Discovery Research